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Background: Therapeutic equivalence of Budesonide/formoterol Easyhaler compared to Symbicort Tur-
buhaler has been previously demonstrated with in vitro and pharmacokinetic studies. This study was
performed to conﬁrm equivalent bronchodilator efﬁcacy of the products in asthmatic patients.
Methods: A randomised, single-dose, 4-period crossover study was carried out in a double-blind, double-
dummy manner in 11 study sites. The studied doses were 320/9 mg and 1280/36 mg of budesonide/for-
moterol delivered by Easyhaler and Turbuhaler. Spirometry was performed before and 10 min, 20 min
and 1, 2, 3, 4, 6, 8, 10 and 12 h after administration of the study treatments. The primary efﬁcacy endpoint
was average 12-h forced expiratory volume in 1 s (FEV1). The secondary efﬁcacy endpoints were
maximum FEV1 and FEV1 at 12 h post-dose.
Results: 72 asthma patients with reversible airway obstruction were randomised to receive study
treatments. 53 patients completed all study periods according to the protocol and had sufﬁcient data
available to calculate the primary endpoint. They were included in the per-protocol analyses. The assay
sensitivity of the study was shown as the common slope of average 12-h FEV1 between doses was 0.063
(95% CI 0.032e0.093) and showed statistical signiﬁcance (p < 0.001). In equivalence testing, the differ-
ence in average 12-h FEV1 between the treatments (Easyhaler-Turbuhaler) was 0.013 l at the lower dose
and 0.028 l at the higher dose, and their 95% conﬁdence intervals (CIs) (0.047 to 0.073 and 0.087 to
0.032, respectively) fell within the range of a clinically non-relevant difference. The results of the sec-
ondary efﬁcacy endpoints were in line with the results of the primary endpoint. All treatments were well
tolerated.
Conclusions: The results conﬁrm equivalent bronchodilator efﬁcacy of Budesonide/formoterol Easyhaler
compared to Symbicort Turbuhaler.
Trial registration: This trial was registered on ClinicalTrials.gov, Identiﬁer: NCT02308098.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Dry powder inhalers (DPIs) containing the corticosteroid
budesonide and the rapid- and long-acting b2-agonist formoterol
have been used for several years for maintenance treatment ofPharma, Volttikatu 8, 70701,
. L€ahelm€a).
Ltd. This is an open access article upatients with moderate-to-severe asthma or chronic obstructive
pulmonary disease (COPD). In some countries, budesonide/for-
moterol combination has also been approved for as-needed treat-
ment in addition to regular maintenance therapy because of the
rapid onset of dose-dependent bronchodilation with formoterol
[1e3]. The bronchodilating effect of the budesonide/formoterol
combination inhaler is more rapid than that of the combination
inhaler containing salmeterol and ﬂuticasone propionate [4].
The Easyhaler DPI products containing salbutamol, formoterol,
beclomethasone dipropionate and budesonide have already beennder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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DPI designed to be simple and easy for different asthma and COPD
patients to use [5]. The appearance of Easyhaler is fairly similar to
that of metered dose inhalers (MDIs) but no hand to mouth coor-
dination in synchronizing the actuation and inhalation is required.
Compared to Turbuhaler the size of the Easyhaler is quite similar
and both inhalers have a dose counter. Where Turbuhaler operation
is based on opening, twisting and inhaling, Easyhaler operational
sequence is shake, click and inhale. Easyhaler also provides dosing
feedback to the patient with the taste of lactose.
Recently, the budesonide/formoterol combination Easyhaler has
been developed and introduced to the market in order to com-
plement the Easyhaler product portfolio. The product has the same
qualitative composition in terms of active substances and the same
pharmaceutical form as the originator product Symbicort® Tur-
buhaler®. Based on in vitro studies and in vivo pharmacokinetic
(PK) studies, Budesonide/formoterol Easyhaler products, 80/4.5,
160/4.5 and 320/9 mg per inhalation, were found to be therapeu-
tically equivalent with the originator products [6e8].
In this study, we sought to conﬁrm equivalent bronchodilator
efﬁcacy of budesonide/formoterol combination delivered via
Easyhaler and Turbuhaler by testing the products at two dose levels
in stable but less than optimally controlled patients with asthma.
2. Methods
2.1. Patients
Asthmatic male and female patients aged 18e70 years were
recruited to the study in Bulgaria and Hungary between December
2014 and May 2015. The patients were eligible for inclusion if they
had asthma diagnosed in accordance with recommendations pro-
vided by the Global Initiative for Asthma [9] for at least 6 months
and if their asthma had been stable with the same regular treat-
ment (e.g. inhaled corticosteroid) for at least 4 weeks prior to
screening. Prebronchodilator forced expiratory volume in 1 s (FEV1)
of the patients had to be 45e90% of the predicted value based on
GLI-2012 reference values [10] and they had to demonstrate
reversible airway function with increase of at least 12% and 200 ml
in FEV1 after inhalation of short-acting b2-agonist (SABA). In
addition, eligible patients showed step-wise reversibility of airway
function with formoterol [11].
The key exclusion criteria were respiratory infection within 4
weeks prior to the screening visit, abnormal serum potassium
value, current smoking and smoking history of more than 10 pack-
years. Corticosteroids other than inhaled corticosteroids, long-
acting b2-agonists (LABAs), xanthine derivatives, and b-blockers
were not allowed within 4 weeks prior to the screening.
To assure stable asthma throughout the study, the pre-dose
(baseline) FEV1 on study treatment day was not to differ more
than 12% compared to the screening prebronchodilator FEV1.
The study was conducted in compliance with the protocol, ICH-
GCP guidelines and the applicable local regulatory requirements.
The study was approved by the central ethics committees of
Bulgaria and Hungary. All patients provided written informed
consent to take part in the study.
2.2. Study design
The study was a randomised, single-dose, 4-period crossover
study carried out in a double-blind, double-dummy manner. Pa-
tients were randomised before ﬁrst study drug administration to
receive all 4 study treatments in random order with 3e14 days
wash-out between the administrations. The randomisation was
performed according to 4-treatment 4-period William's design.The study treatments were 1 and 4 inhalation(s) of Budesonide/
formoterol Easyhaler® 320/9 mg/inhalation (Orion Pharma, Finland)
and Symbicort® Turbuhaler® 320/9 mg/inhalation (AstraZeneca,
UK); the formoterol doses were 9 mg and 36 mg. Corresponding
number of placebo inhalation(s) were given from Easyhaler or
Turbuhaler. The study treatment administrations took place at the
study centres and the trained staff instructed the patients on cor-
rect inhalation technique, which was practised with placebo
inhalers.
During the study, the patients continued the use of their regular
asthma medication with a constant dose. Inhaled SABA and anti-
cholinergics, oral sympathomimetics, cough medicines containing
salbutamol or ephedrine, and pseudoephedrine-containing anti-
histamines were not allowed before spirometry. If additional
bronchodilating relief was needed during a study treatment day,
salbutamol inhalation aerosol was given as a rescue medication.
Serial spirometry was performed up to 12 h after dosing using a
KoKo® spirometer in combination with eSP™ Spirometry Systems
(nSpire Health, US). Lung function tests were performed using
current joint ERS/ATS spirometry recommendations [12] and were
quality controlled centrally. At least 3 successive manoeuvres at
baseline and at least 2 successive manoeuvres after the study
treatment administration at each time point were performed. Up to
5 manoeuvres were carried out per time point and the highest
acceptable FEV1 value was used for analysis.
The safety of the study drugs was evaluated based on adverse
events (AEs). Other safety assessments consisting of physical ex-
amination, vital signs, electrocardiogram [ECG] and laboratory tests
were carried out at screening and end-of-study visits.
2.3. Endpoints
Spirometry was performed before and 10min, 20min and 1, 2, 3,
4, 6, 8, 10 and 12 h after administration of the study treatment. The
primary efﬁcacy endpoint was the average 12-h FEV1 determined
from serial spirometry and calculated on the basis of area under
curve (AUC) of FEV1 (AUC divided by observation time). Single
missing FEV1 values were imputed by weighted mean of FEV1
values right before and after the missing value. Missing baseline
FEV1 values could not be estimated. The secondary efﬁcacy end-
points were maximum FEV1 over the 12-h serial assessments and
FEV1 at 12 h post-dose (i.e. FEV1 at the trough of the effect).
The number of patients using rescue medication during each
study treatment daywas recorded. AEs were collected and reported
per study treatment. Changes in physical examination, vital signs,
ECG and laboratory tests between screening and end-of-studywere
evaluated.
2.4. Statistics
The sample size calculation was based on showing the higher
dose to be statistically signiﬁcantly superior to the lower dose.
Signiﬁcance level was 0.05, average 12-h FEV1 for the higher dose
was assumed to be 3.33% higher than for the lower dose, and power
was 80%. The sample size calculation resulted in 72 patients.
In primary efﬁcacy analyses (per-protocol [PP] analyses) only
the patients who completed all 4 study periods without protocol
violations andwithout the use of rescuemedication, were included.
Intention-to-treat (ITT) analyses included all patients who had data
from at least one period.
Firstly, it was tested with the common slope model if the
average 12-h FEV1 is the same for both of the doses [13]. It was
tested if the slope of log of dose is statistically signiﬁcantly different
from zero, i.e. if the study is sensitive enough to separate the doses
from each other. Secondly, the equivalence of study treatments
Table 1
Baseline characteristics of the randomised patients.
Characteristic Total N ¼ 72
Sex, n (%)
Male 46 (63.9)
Female 26 (36.1)
Race, n (%)
Caucasian 72 (100)
Age, years
Mean (SD) 51.4 (13.5)
Range 19e70
FEV1, l
Mean (SD) 1.92 (0.54)
Range 0.97e3.58
FEV1 of predicted value, %
Mean (SD) 62.2 (12.1)
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conﬁdence intervals (CIs) between Easyhaler and Turbuhaler. An
analysis of covariance (ANCOVA) model was used [13]. It was pre-
deﬁned that the treatments would be considered equivalent if the
95% CIs for the treatment differences with respect to the primary
endpoint were within ±0.170 l.
PP and ITT analyses were also performed for the secondary ef-
ﬁcacy endpoints (maximum FEV1 and FEV1 at 12 h post-dose). The
applied statistical methods were the same as in the primary
equivalence analyses except that there were no pre-speciﬁed
equivalence criteria. Relative potency of average 12-h FEV1 be-
tween Easyhaler and Turbuhaler was an additional analysis
without a pre-speciﬁed equivalence criterion [14,15].
Statistical analyses were performed with SAS/STAT® software.
Range 45.3e88.6
Duration of asthma, years
Mean (SD) 13.0 (10.4)
Range 1.2e41.73. Results
3.1. Disposition of patients and baseline characteristics
In total, 109 patients were screened for the study and 72 were
randomised to receive study treatment (Fig. 1). The majority of the
screening failures were due to the step-wise reversibility test with
formoterol (n ¼ 20). All 72 patients were included in the ITT ana-
lyses and 53 patients fulﬁlled the requirements for PP analyses.
Baseline characteristics of the randomised patients are shown in
Table 1. Almost all patients (n ¼ 69, 95.8%) used salbutamol on an
as-needed basis for the treatment of asthma andmost of themwere
on inhaled corticosteroid treatment (n ¼ 61, 84.7%).Fig. 2. Mean FEV1 curves for 12 h after administration of study treatments.3.2. Efﬁcacy
In assay sensitivity testing, the estimates of average 12-h FEV1
were 2.324 l (95% CI 2.287e2.360) for Easyhaler and 2.332 l (95% CI
2.295e2.368) for Turbuhaler at the 320/9 mg dose and 2.411 l (95%
CI 2.374e2.447) for Easyhaler and 2.419 l (95% CI 2.382e2.455) for
Turbuhaler at the 1280/36 mg dose. The common slope was 0.063
(95% CI 0.032e0.093), and showed statistical signiﬁcance
(p < 0.001), indicating a positive relation between the treatment
dose and average 12-h FEV1. The difference between doses andFig. 1. Patient disposition.similarity of the products within doses was seen in FEV1 curves
from zero to 12 h after study treatment administration (Fig. 2).
The estimates of average 12-h FEV1 for all treatments in equiv-
alence testing are given in Table 2. The difference in average 12-h
FEV1 between the treatments was negligible both at the lower
dose (0.013 l, 95% CI 0.047 to 0.073) and at the higher dose
(0.028 l, 95% CI 0.087 to 0.032) and fell within the equivalence
margins (Fig. 3).
The estimates of maximum FEV1 and FEV1 at 12 h post-dose are
presented in Table 2. The estimated difference in maximum FEV1
between the treatments (Easyhaler-Turbuhaler) was small both at
the lower dose (0.002 l, 95% CI 0.058 to 0.062) and at the higher
dose (0.022 l, 95% CI 0.081 to 0.037). There was no clinically
relevant difference in FEV1 at 12 h post-dose between Easyhaler
and Turbuhaler, as the estimated difference was 0.002 l (95% CI
0.084 to 0.081) at the lower dose and 0.008 l (95% CI 0.074 to
0.090) at the higher dose. The ITT analyses results of the primary
and secondary endpoints were in agreement with the PP results.
In relative potency analysis, parallelism was established be-
tween the two treatments and the dose response was signiﬁcant
(p < 0.0001). Relative potency of average 12-h FEV1 between
Easyhaler and Turbuhaler was 1.1 (90% CI 0.62e2.2).
Rescue medication (salbutamol) was used by 2 patients who
both had had 1 inhalation from Turbuhaler as the study treatment.3.3. Safety
There were no discontinuations due to AEs or serious AEs. 6
Table 2
Estimates and 95% CIs for primary and secondary efﬁcacy endpoints in equivalence testing (PP, n ¼ 53).
Treatment Baseline FEV1 (l) Estimated mean (95% CI)
Average 12-h FEV1 (l) Max FEV1 (l) 12 h post-dose FEV1 (l)
Easyhaler 320/9 mg 1.932 2.334 (2.292e2.376) 2.526 (2.484e2.568) 2.260 (2.202e2.318)
Turbuhaler 320/9 mg 1.888 2.321 (2.279e2.364) 2.524 (2.482e2.566) 2.261 (2.203e2.320)
Easyhaler 1280/36 mg 1.924 2.401 (2.359e2.443) 2.592 (2.551e2.634) 2.358 (2.300e2.416)
Turbuhaler 1280/36 mg 1.906 2.429 (2.387e2.471) 2.614 (2.573e2.656) 2.350 (2.292e2.408)
Fig. 3. Average 12-h FEV1 comparison between Budesonide/formoterol Easyhaler and
Symbicort Turbuhaler.
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equally distributed between the study treatments. There were no
clinically signiﬁcant new abnormal ﬁndings in physical examina-
tion, vital signs, ECG or laboratory parameters at the end-of-study
compared to screening.
4. Discussion
In this double-blind, double-dummy, randomised, 4-way cross-
over study, two single inhaled doses of budesonide/formoterol,
320/9 mg and 1280/36 mg, were compared between Budesonide/
formoterol Easyhaler and Symbicort Turbuhaler with respect to
bronchodilating effects. The results show that the study was sen-
sitive enough to separate the tested doses from each other and that
the products are equivalent within dose levels. In addition, the
maximum response and the duration of effect are similar after both
products.
This study with pharmacodynamic (PD) endpoints was
designed based on EMA guideline for demonstration of therapeutic
equivalence between two orally inhaled products (OIPs) [16], and it
was a continuum to the previously conducted PK studies [6]. A
stepwise development, in vitro comparison followed by PK com-
parison and ﬁnally by PD evaluation, has been required for a second
entry product in Europe since 2009. Depending on the data, an
approval of a product is possible after each step. In the US, all as-
pects of comparative testing are required to establish bioequiva-
lence for inhalation products [17]. This is so called weight of
evidence approach. During the recent years, the FDA has published
several product speciﬁc draft guidances (on albuterol and ﬂutica-
sone propionate; salmeterol in 2013 and on budesonide;formoterol in 2015) [18e20]. In those guidances the PD/clinical
endpoint study includes placebo dosing but testing of 2 dose levels
(of reference product) is required only for albuterol. With respect of
the inhaler characteristics, practically a copy of the originator
inhaler (similar operating procedure, size and shape) is required.
In patient selection a positive step-wise reversibility test with
formoterol was required to ensure that only asthmatics with po-
tency to improve in lung function with increasing LABA doses were
included. A step-wise reversibility test, either with formoterol or
salbutamol, has been used successfully also earlier although it in-
creases the number of screening failures [1,11]. In our study the test
doubled the number of patients not eligible for randomisation.
The pre-study hypotheses were that there would be a difference
in the average 12-h FEV1 between the formoterol 9 and 36 mg doses
and that the tested products would be equivalent in terms of
bronchodilator efﬁcacy at both dose levels. Based on the sample
size calculation a study with 72 patients was needed. In the
calculation 15% dropout rate was assumed but only 5 patients (7%)
discontinued. On the other hand, the number of patients excluded
from the PP analysis due to other reasons was fairly high (14 pa-
tients). Majority of the exclusions related to FEV1 measurements
which were laborious and had to be performed according to strict
criteria. Only patients to whom the primary endpoint was available
for all study periods were included in the PP analysis. It should be
noted that single missing FEV1 values were imputed but if several
consecutive values or baseline were missing the primary endpoint
was not calculated. However, the results of the analysis with pa-
tients to whom the primary variable could be calculated for at least
one period (ITT, N ¼ 72) were in line with the PP results, and
conﬁrm robust study results.
It is crucial that a study has assay sensitivity to discriminate
between two products and to identify clinically relevant differences
that might exist between them [16]. Therefore, 2 dose levels from
both products were studied. Assay sensitivity in the current study
was demonstrated by the positive and statistically signiﬁcant
relationship between treatment dose and average 12-h FEV1. The
result is in accordance with published studies. Maesen and co-
workers compared bronchodilator effects of 12, 24 and 48 mg for-
moterol via DPI, 12 mg formoterol via MDI and placebo in 30 asth-
matic patients [21]. They found statistically signiﬁcant differences
in FEV1AUC over 12 h between placebo and all formoterol doses,
and between the 12 and 48 mg doses inhaled via a DPI. A study with
formoterol Easyhaler product also found 48 mg dose of formoterol
superior to 12 mg with the same endpoint [22]. In a further placebo-
controlled study in 31 reversible asthma patients, 4.5, 9, 18 and
36 mg formoterol doses were administered via Turbuhaler [2]. The
36 mg dose resulted in a maximum FEV1 value of 2.65 ± 0.69 l,
whichwas statistically signiﬁcantly higher than themaximal values
obtained after the administration of the lower doses. Therefore,
there is abundant evidence that with appropriate patient selection
a bronchodilation study would fulﬁl the requirement of the 36 mg
dose being statistically superior to the 9 mg dose.
In equivalence testing, the estimates of average 12-h FEV1 were
similar for Budesonide/formoterol Easyhaler and Turbuhaler at
both dose levels. The treatment differences at both dose levels
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relevant. The results for the secondary efﬁcacy endpoints,
maximum FEV1 and FEV112 h post-dose, supported the conclusions
drawn from the analyses of the primary efﬁcacy endpoint. The re-
sults of the current study conﬁrm the equivalent bronchodilator
efﬁcacy of the products in asthmatic patients in a clinical setting.
The results are consistent with previous PK studies that have
shown equivalent lung dose and systemic exposure of budesonide/
formoterol combination via Easyhaler and Turbuhaler [6].
The OIP guideline suggests performing the comparison between
the products additionally on the dose scale [16]. Accordingly, in this
study the analysis on dose scale, i.e. the estimation of the relative
potency, was carried out as an additional analysis without a pre-
speciﬁed equivalence criterion. The estimate for the relative po-
tency was close to one but the CI was rather wide. This was an
expected result based on the simulations andmodelling of our own
data with formoterol [22]. In a study by Miller and co-workers
relative potency was the primary analysis, and they succeeded in
demonstrating equivalence (with limits 0.67 to 1.5) between
budesonide/formoterol pMDI and formoterol DPI in average 12-h
FEV1 [14]. In their study 4.5, 9 and 18 mg formoterol doses were
employed and number of patients was considerably higher
(N ¼ 201) than in our study. For the dose scale analysis the lower
dose should be low enough to increase the precision of the dose-
response characterization and to decrease the width of the CI of
relative potency [17].
Bronchoprotection studies assessing the potency of a drug to
protect against provocation with e.g. methacholine are an alter-
native way to compare bronchodilator drug efﬁcacy. They have
been argued to have steeper dose-response curves, and therefore,
being more sensitive than bronchodilation studies [23,24]. There
are, however, many methodological challenges related to per-
forming bronchoprotection studies. They require a high degree of
standardisation and are also less acceptable by patients because of
bronchoconstrictive effects.
There were no unexpected safety ﬁndings in this study. The
number of reported AEs was low indicating good safety of both
products.
In conclusion, the results of the primary efﬁcacy endpoint,
average 12-h FEV1, conﬁrm equivalent bronchodilator efﬁcacy of
Budesonide/formoterol Easyhaler compared to Turbuhaler. The
results of the secondary efﬁcacy endpoints further strengthen the
conclusion of therapeutic equivalence between the products.Conﬂict of interest
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